AMENDMENTS TO THE SPECIFICATION

Please insert the paper copy of the sequence listing, submitted herewith, into the specification.

Please amend Paragraph [0023] (pages 7-8) as follows:

Figure 3 shows inhibition of microtubule nucleation by portions of the PN2-3 fragment of CPAP. (A) Diagram depicting cDNA constructs and synthetic peptides encoding various portions of the PN2-3 fragment of CPAP. (B) Coomassie-stained polyacrylamide gel showing affinity-purified GST-truncated PN2-3 CPAP fusion proteins. (C and D) Results of an *in vitro* microtubule nucleation assay showing the effect of truncated PN2-3 CPAP fusion proteins (C) and the synthetic peptide derived from PN2-3 (D) on microtubule nucleation. (E) Quantitative analysis of the inhibitory effects observed in (C). (F) Location of the proline substitutions in four mutated PN2-3 polypeptides and the predicted relative probability (compared to the wild-type sequence (i.e., SEQ ID NO: 3 ~~1~~)) that each mutated polypeptide will form an α-helical domain. (G) Results of an *in vitro* microtubule nucleation assay using the polypeptides of (F) along with wild-type PN2-3.